1. Home
  2. LYRA vs XHLD Comparison

LYRA vs XHLD Comparison

Compare LYRA & XHLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • XHLD
  • Stock Information
  • Founded
  • LYRA 2005
  • XHLD 2011
  • Country
  • LYRA United States
  • XHLD United States
  • Employees
  • LYRA N/A
  • XHLD N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • XHLD
  • Sector
  • LYRA Health Care
  • XHLD
  • Exchange
  • LYRA Nasdaq
  • XHLD NYSE
  • Market Cap
  • LYRA 15.0M
  • XHLD 17.6M
  • IPO Year
  • LYRA 2020
  • XHLD 2025
  • Fundamental
  • Price
  • LYRA $9.40
  • XHLD $0.40
  • Analyst Decision
  • LYRA Buy
  • XHLD Strong Buy
  • Analyst Count
  • LYRA 2
  • XHLD 1
  • Target Price
  • LYRA $16.00
  • XHLD $8.00
  • AVG Volume (30 Days)
  • LYRA 1.9M
  • XHLD 1.1M
  • Earning Date
  • LYRA 08-13-2025
  • XHLD 08-20-2025
  • Dividend Yield
  • LYRA N/A
  • XHLD N/A
  • EPS Growth
  • LYRA N/A
  • XHLD N/A
  • EPS
  • LYRA N/A
  • XHLD N/A
  • Revenue
  • LYRA $1,185,000.00
  • XHLD $3,115,000.00
  • Revenue This Year
  • LYRA N/A
  • XHLD $42.64
  • Revenue Next Year
  • LYRA $1,286.17
  • XHLD $65.31
  • P/E Ratio
  • LYRA N/A
  • XHLD N/A
  • Revenue Growth
  • LYRA N/A
  • XHLD N/A
  • 52 Week Low
  • LYRA $3.81
  • XHLD $0.37
  • 52 Week High
  • LYRA $37.50
  • XHLD $8.54
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 45.31
  • XHLD N/A
  • Support Level
  • LYRA $10.15
  • XHLD N/A
  • Resistance Level
  • LYRA $14.88
  • XHLD N/A
  • Average True Range (ATR)
  • LYRA 2.03
  • XHLD 0.00
  • MACD
  • LYRA -0.67
  • XHLD 0.00
  • Stochastic Oscillator
  • LYRA 0.42
  • XHLD 0.00

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About XHLD TEN HOLDINGS INC

TEN Holdings Inc is a provider of event planning, production, and broadcasting services. The company produces virtual and hybrid events and physical events. Virtual and hybrid events involve virtual and hybrid event planning, production and broadcasting services, and continuing education services, all of which are supported by its Xyvid Pro Platform. Physical events involve live streaming and video recording of physical events. The Company operates business as one operating segment which includes two revenue types: Hybrid and Virtual Events and Physical Events.

Share on Social Networks: